Enclomiphene Citrate in Children Under 12: What Clinicians and Parents Need to Know About Off-Label Use

What Is Enclomiphene Citrate and How Does It Work?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It acts as a selective estrogen receptor modulator (SERM) at hypothalamic estrogen receptors, blocking negative feedback from circulating estradiol and prompting increased secretion of gonadotropin-releasing hormone (GnRH). That cascade drives the pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulates testicular testosterone production [1].

Why the Isomer Distinction Matters

Clomiphene citrate is a racemic mixture containing both the cis-isomer (zuclomiphene) and the trans-isomer (enclomiphene). Zuclomiphene has a long half-life and can accumulate, potentially causing persistent estrogenic effects. Enclomiphene was separated and developed specifically to avoid that accumulation [2]. In adult men with secondary hypogonadism, Phase II and Phase III trials (Androxal program, N approximately 200 per arm) showed that 12.5 mg and 25 mg oral doses raised serum testosterone into the normal adult male range while preserving spermatogenesis, unlike exogenous testosterone therapy [3].

The HPG Axis in Children Under 12

The hypothalamic-pituitary-gonadal (HPG) axis in prepubertal children is in a physiologically suppressed state often called the "juvenile pause." GnRH pulse frequency is low, LH and FSH are near the lower limit of detection, and gonadal sex steroid production is minimal [4]. Applying a pharmacologic stimulus to this quiescent axis carries risks that simply do not exist in adult men, including premature activation of puberty, acceleration of bone age, and premature epiphyseal fusion that could reduce final adult height.

FDA Regulatory Status: No Approval, No Pediatric Studies Required

Enclomiphene citrate was reviewed under the NDA pathway (NDA 022162) as a treatment for secondary hypogonadism in adult men. The FDA issued a Complete Response Letter and the drug never received final approval [5]. Because the target population was adult males seeking fertility preservation, the FDA did not require pediatric studies under the Pediatric Research Equity Act (PREA), which mandates pediatric investigation only when a drug is approved and the labeled indication plausibly extends to children [6].

What PREA and BPCA Mean for Off-Label Risk

The Best Pharmaceuticals for Children Act (BPCA) and PREA together create a system where drugs commonly used off-label in children can be studied with NIH or FDA incentives. Enclomiphene has not been listed on any NIH BPCA priority list for pediatric study as of 2025 [6]. That absence signals a regulatory consensus: there is no recognized pediatric need sufficient to justify formal trials in children under 12.

Compounded Enclomiphene and Pediatric Exposure Risk

A meaningful fraction of enclomiphene used in the United States today comes from 503A compounding pharmacies rather than a finished pharmaceutical product. Compounded preparations lack the bioavailability standardization and quality controls of an NDA-approved product. The FDA's guidance on compounded SERMs makes clear that prescribing compounded enclomiphene to children carries layered risks: dose inaccuracy, excipient exposure, and the absence of any pediatric pharmacokinetic data [5].

Clinical Pharmacokinetics: Why Adult PK Data Cannot Be Extrapolated to Children

In adult males, enclomiphene reaches peak plasma concentration (Tmax) roughly 2 hours after a 25 mg oral dose, with a mean half-life of approximately 10 hours [3]. Body weight, hepatic CYP enzyme activity, and plasma protein binding all differ substantially in prepubertal children compared with adult men. Pediatric pharmacokinetic modeling for SERMs has been conducted for tamoxifen in children with McCune-Albright syndrome, and those data show that dose-normalized exposure in younger children can be two to three times higher than in adults due to differences in volume of distribution and metabolic clearance [7].

Bone Age Acceleration: A Distinct Pediatric Risk

Sex steroids are the primary drivers of growth plate advancement. Even modest increases in estradiol or testosterone in a prepubertal child can accelerate bone age faster than chronological age, compressing the window for linear growth. A 2019 review in the Journal of Clinical Endocrinology and Metabolism noted that estrogen is the dominant regulator of epiphyseal fusion in both sexes, and that inadvertent estrogen exposure from SERM partial agonism carries measurable risk of early plate closure [8]. Enclomiphene's residual estrogenic agonist activity at peripheral tissues means this risk cannot be dismissed simply because the drug is classified as an antagonist at the hypothalamus.

Gonadotropin Surge in an Unprepared Axis

Flooding a quiescent HPG axis with elevated LH and FSH could trigger premature testicular or ovarian activation. In boys, this resembles gonadotropin-dependent precocious puberty; in girls, it could drive premature follicular recruitment. Neither scenario has been studied under controlled conditions with enclomiphene in children under 12, and neither has a clearly safe management pathway in the published literature [4].

What the Endocrine Society and PES Guidelines Actually Say

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy in men explicitly states that clomiphene and its isomers are appropriate only in adult males with secondary hypogonadism who desire fertility preservation [9]. The guideline does not address pediatric use, which itself reflects the consensus that no such use is indicated.

The Pediatric Endocrine Society's guidance on differences of sexual development (DSD) and hypogonadism in children recommends human chorionic gonadotropin (hCG) stimulation testing for diagnostic purposes and, where treatment is needed before puberty, low-dose sex steroid replacement using age-appropriate protocols rather than hypothalamic-axis stimulants [10].

A three-question clinical decision framework helps clinicians receiving off-label enclomiphene requests for children under 12:

1. Is there a defined diagnosis of secondary hypogonadism confirmed by repeated low LH and FSH with low sex steroids, in the context of a pituitary or hypothalamic lesion? If not, enclomiphene has no rational target.
2. Has a pediatric endocrinologist reviewed the case? Off-label SERM use in prepubertal children should never proceed without subspecialty input.
3. Are there guideline-endorsed alternatives (hCG, recombinant FSH, GnRH analog, or watchful waiting) that have not yet been tried? If yes, those must come first.

Conditions Sometimes Cited to Justify Off-Label Use in Children

Hypogonadotropic Hypogonadism (HH)

Congenital hypogonadotropic hypogonadism (CHH), including Kallmann syndrome, is diagnosed in approximately 1 in 30,000 males [11]. Children with CHH may present before or during the expected pubertal window with absent GnRH secretion. The standard approach in children under 12 is observation, because the expected pubertal window has not yet arrived. In boys approaching mid-puberty age (12 to 14), pulsatile GnRH therapy or hCG plus recombinant FSH are the treatments with controlled trial support, not enclomiphene [11].

Delayed Puberty

Constitutional delay of growth and puberty (CDGP) is the most common cause of delayed puberty and is a self-resolving condition. Endocrine Society guidelines support short-course low-dose testosterone in boys 14 and older with significant psychosocial impact and confirmed constitutional delay, not enclomiphene, and certainly not in children under 12 [9].

Anorchia and Primary Hypogonadism

Enclomiphene works by stimulating the HPG axis above the level of the testes. In primary hypogonadism (absent or non-functioning testes), the testes cannot respond to elevated LH. Prescribing enclomiphene in this context provides no benefit and exposes the child to all risks with zero therapeutic upside.

Evidence Summary: What the Published Literature Actually Contains

A PubMed search combining "enclomiphene" AND "pediatric" OR "child" OR "adolescent" returns zero controlled trials as of mid-2025 [1]. The entire enclomiphene clinical trial database is adult-male. The three Phase III trials in the Androxal program enrolled men 18 years and older with BMI between 25 and 42 kg/m² and secondary hypogonadism confirmed by morning testosterone below 300 ng/dL on two separate measurements [3].

Case reports of SERM use in adolescent males (14 to 17 years) with constitutional delay exist for clomiphene citrate, not enclomiphene specifically, and even those reports involve post-pubertal or mid-pubertal boys rather than prepubertal children under 12 [12].

A 2021 systematic review in the Journal of Clinical Endocrinology and Metabolism examining SERMs for male hypogonadism identified 14 randomized controlled trials, all exclusively in adult populations. The authors explicitly noted that "extrapolation to pediatric populations is not supported by existing evidence" [13].

Safety Signals From Adult Data That Are Amplified in Children

Visual Disturbances

Clomiphene citrate is associated with visual disturbances in up to 1.5% of users, including blurred vision and scotomata [12]. The mechanism is direct retinal estrogen receptor modulation. Children's developing visual systems may carry heightened sensitivity to this effect, though no pediatric data exist to quantify the risk.

Mood and Behavioral Effects

Estrogen receptors are expressed throughout the developing brain. SERMs that modulate these receptors during periods of active neurodevelopment could theoretically affect mood regulation, cognition, and behavioral development. The adult literature documents mood changes in a minority of clomiphene users, but the developing pediatric CNS represents a categorically different risk environment [4].

Hepatic Metabolism Burden

Enclomiphene is hepatically metabolized. Children under 12 have lower body weight and different hepatic enzyme expression profiles than adults. Without pediatric pharmacokinetic studies, no safe dose can be calculated using adult data alone. The American Academy of Pediatrics has repeatedly emphasized that weight-based dose scaling from adult data is insufficient for drugs with complex hepatic metabolism [14].

Established Pediatric Alternatives With Evidence Support

When a prepubertal boy or girl genuinely requires gonadotropin-axis intervention before age 12, the following options have at least some trial data:

Human chorionic gonadotropin (hCG): Acts directly on testicular LH receptors. Used diagnostically and therapeutically in boys with cryptorchidism and selected HH cases. The FDA has approved hCG for cryptorchidism in boys [15].

Recombinant FSH (follitropin alfa or beta): Used in combination with hCG for spermatogenesis induction in adult HH; some protocols are adapted for adolescents approaching puberty under subspecialist supervision [11].

GnRH pulse therapy: Pulsatile GnRH via subcutaneous pump is the most physiologic treatment for HH at any age. Small series in children approaching puberty show successful pubertal induction without the bone-age acceleration risk of sex steroids [11].

Watchful waiting: For constitutional delay and most forms of prepubertal hypogonadism in children under 12, doing nothing and monitoring bone age every six months is the most defensible approach, supported by PES guidance [10].

Counseling Families Requesting Enclomiphene for Children Under 12

Families sometimes arrive at telehealth platforms requesting enclomiphene for a child after reading adult forums or social media content. A clear, respectful clinical conversation should cover four points:

First, explain the mechanism: enclomiphene works by disrupting the brain's hormonal thermostat, and in a child whose thermostat is deliberately set to "off" by normal developmental biology, forcing it "on" pharmacologically could cause more harm than the original concern.

Second, present the evidence gap honestly. There are zero pediatric trials. This is not a gap that can be bridged by adult data or by theoretical reasoning alone.

Third, refer to a pediatric endocrinologist. The American Academy of Pediatrics recommends subspecialty referral for any child with suspected hypogonadism before initiating any hormonal therapy [14].

Fourth, document the conversation thoroughly. Off-label prescribing in children carries legal and ethical weight beyond that in adults, and thorough documentation protects both the patient and the clinician.

Monitoring If a Pediatric Endocrinologist Proceeds Despite Absence of Evidence

In rare circumstances, a board-certified pediatric endocrinologist may decide, after exhausting all alternatives and obtaining fully informed consent, to use a SERM off-label in a child approaching the edge of the under-12 age window (for example, an 11-year-old male with confirmed CHH and significant psychosocial burden). If that decision is made, minimum monitoring should include:

• Bone age X-ray (left hand and wrist) at baseline and every 6 months [8]
• Morning LH, FSH, testosterone, and estradiol at baseline, 4 weeks, and every 3 months
• Testicular volume by Prader orchidometer at baseline and every 3 months in boys
• Ophthalmic examination at baseline given the visual disturbance signal in the adult literature [12]
• Liver function panel at baseline and 3 months given hepatic metabolism
• Growth velocity documentation at every visit

No validated monitoring protocol for enclomiphene in children under 12 exists in any published guideline. The framework above is adapted from monitoring standards used in pediatric GnRH analog and hCG protocols [10, 11].